Metastatic Solid Tumors

Also known as: Metastatic Solid Tumor

DrugDrug NameDrug Description
DB09037PembrolizumabPembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptor. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype with the containing a stabilizing S228P Fc mutation.[A18829] It contains 32 cysteine residues and the complete folded molecule includes 4 disulfide linkages as interchain bonds and 23 interchain bonds.[F136] It was developed by Merck & Co and firstly approved for the treatment of metastatic malignant melanoma. This is the first approved therapy against PD-1.[A7624] It was approved firstly by the FDA on September 4, 2014.[L2954] Its approval in melanoma was extended to several countries such as Australia, Israel, Korea, Macau, the European Union and the United Arab Emirates.[A33350] On June 12, 2018, Pembrolizumab was approved for the treatment of cervical cancer under the status of accelerated approval.[L2955]
DrugDrug NamePhaseStatusCount
DB12565Abexinostat1Active Not Recruiting1
DB06013Aldoxorubicin1Completed1
DB11945Avelumab1Recruiting1
DB00958Carboplatin1Completed2
DB05239Cobimetinib1Recruiting1
DB11986Entrectinib1Active Not Recruiting1
DB00530Erlotinib1Completed1
DB00441Gemcitabine1Completed1
DB00441Gemcitabine1Recruiting1
DB11886Infigratinib1Completed1
DB06186Ipilimumab1Recruiting1
DB11740MK-17751Active Not Recruiting1
DB09035Nivolumab1Recruiting1
DB06306Onalespib1Completed1
DB12638PU-H711Active Not Recruiting1
DB01229Paclitaxel1Completed1
DB01229Paclitaxel1Recruiting1
DB06589Pazopanib1Active Not Recruiting1
DB01132Pioglitazone1Completed1
DB01030Topotecan1Completed1
DB12400Voxtalisib1Completed1
DB12498Mogamulizumab1 / 2Recruiting1
DB00619Imatinib2Withdrawn1